Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Press Releases
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
23 July 2024
GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update
11 July 2024
GenSight Biologics Launches Newsletter for Retail Investors
20 June 2024
GenSight Biologics renegotiates financial obligations and provides operational updates
04 June 2024
GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings
03 June 2024
GenSight Biologics Appoints William Monteith to its Board of Directors
30 May 2024
Gensight Biologics announces the approval of all resolutions supported by the Board of Directors at its Combined General Meeting
07 May 2024
GenSight Biologics announces the availability of a prospectus in connection with the listing of new shares on Euronext Paris
07 May 2024
Annual General Meeting on May 29, 2024
07 May 2024
GenSight Biologics announces a successful offering for an amount over €9.2 million
17 April 2024
GenSight Biologics Announces the Filing of its 2023 Universal Registration Document
1
2
3
4
5
6
…
24
View next 9 articles
Go back to the page of the page